What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations from its registered office in Sidhpur, North Gujarat, generating Rs 15.5852 crore of revenue in FY26, up roughly 12% from Rs 13.86 crore the prior year. The single biggest cost line is raw materials at 77% of revenue, with the company approving related-party purchases of psyllium husk from Urvesh and Company up to Rs 200 lakhs, signalling that ingredient is a key input. Employee cost runs at 6% of revenue and other operating expenses at 10.7%, while depreciation (0.9%) and capex (0%) are negligible. Profit after tax rose to Rs 0.7047 crore (a 72.8% increase) on an FY26 ebitda margin of 7.08%. The company carries no long-term borrowings, holds Rs 164.48 lakhs of cash, and reported net worth of Rs 384.34 lakhs as of 31 March 2026.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from UNJHA FORMULATIONS LTD.'s filed financials and exchange disclosures
UNJHA FORMULATIONS LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Yes. Over the trailing twelve months UNJHA FORMULATIONS LTD. reported a net profit of ₹1 Cr on revenue of ₹16 Cr.
Not in the latest reported year — UNJHA FORMULATIONS LTD.'s dividend payout for FY26 was nil.
Effectively yes. It holds ₹2 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, UNJHA FORMULATIONS LTD. ranks 14 of 169 in Pharmaceuticals — cheaper than 92% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session UNJHA FORMULATIONS LTD. moves 2.02% — that is the median absolute close-to-close move across its last 266 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by UNJHA FORMULATIONS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
